Impact of CYP2D6 Genotype on Amitriptyline Efficacy for the Treatment of Diabetic Peripheral Neuropathy: A Pilot Study

References

• International Diabetes Foundation . www.idf.org .
   Google Scholar
• Boulton AJM . Management of diabetic peripheral neuropathy . Clin. Diabetes23 , 9 – 15 ( 2005 ).
   Google Scholar
• Boulton AJ , GriesFA , JervellJA . Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy . Diabet. Med.15 , 508 – 514 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Ulugol A , KaradagHC , TamerM , FiratZ , AslantasA , DokmeciI . Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats . Neurosci. Lett.328 , 129 – 132 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Devi P , MadhuK , GanapathyB , SarmaG , JohnL , KulkarniC . Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy . Indian J. Pharmacol.44 , 51 – 56 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Gore M , BrandenburgNA , HoffmanDL , TaiK-S , StaceyB . Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives . J. Pain7 , 892 – 900 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Attal N , CruccuG , HaanpääMet al. EFNS guidelines on pharmacological treatment of neuropathic pain . Eur. J. Neurol.13 , 1153 – 1169 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Callaghan BC , ChengHT , StablesCL , SmithAL , FeldmanEL . Diabetic neuropathy: clinical manifestations and current treatments . Lancet Neurol.11 , 521 – 534 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Steimer W , ZöpfK , Von AmelunxenSet al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy . Clin. Chem.51 , 376 – 385 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Chetty S , BaalbergenE , BhigjeeAIet al. Clinical practice guidelines for management of neuropathic pain: expert panel recommendations for South Africa . SAMJ.102 , 312 – 325 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• The Human Cytochrome P450 (CYP) Allele Nomenclature Database . www.cypalleles.ki.se/ .
   Google Scholar
• Teh LK , BertilssonL . Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance . Drug Metab. Pharmacokinet.27 , 55 – 67 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Zhou S-F , LiuJ-P , ChowbayB . Polymorphism of human cytochrome P450 enzymes and its clinical impact . Drug Metab. Rev.41 , 89 – 295 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , SangkuhlK , Whirl-CarrilloM , KleinT , LeederJS . Prediction of CYP2D6 phenotype from genotype across world populations . Genet. Med.19 , 69 – 76 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Llerena A , DoradoP , Peñas-LledóEM . Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity . 10 ( 1 ), 17 – 28 ( 2009 ).
   Google Scholar
• Llerena A , NaranjoMEG , Rodrigues-SoaresF , Penas-LledóEM , FariñasH , Tarazona-SantosE . Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations . Expert Opin. Drug Metab. Toxicol.10 ( 11 ), 1569 – 1583 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Caudle KE , DunnenbergerHM , FreimuthRRet al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) . Genet. Med.19 ( 2 ), 215 – 223 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Hicks JK , SwenJJ , ThornCFet al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants . Clin. Pharmacol. Ther.93 , 402 – 408 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Hicks JK , SangkuhlK , SwenJJet al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update . Clin. Pharmacol. Ther. doi:10.1002/cpt.597 ( 2016 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Jiang Z-P , ShuY , ChenX-Pet al. The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects . Eur. J. Clin. Pharmacol.58 , 109 – 113 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Mayfield JA , SugarmanJR . The use of the Semmes–Weinstein monofilament and other threshold tests for preventing foot ulceration and amputation in persons with diabetes . J. Fam. Pract.49 ( 11 ), S17 – S17 ( 2000 ).
   PubMedGoogle Scholar
• Dodgen TM , HochfeldWE , FicklHet al. Introduction of the AmpliChip CYP450 test to a South African cohort: a platform comparative prospective cohort study . BMC Med. Genet.14 , 20 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• The Human Cytochrome P450 (CYP) Allele Nomenclature Database . www.cypalleles.ki.se/cyp2d6.htm .
   Google Scholar
• Twist GP , GaedigkA , MillerNAet al. Constellation: a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences . NPJ Genom. Med.1 , 15007 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , SimonSD , PearceRE , BradfordLD , KennedyMJ , LeederJS . The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype . Clin. Pharmacol. Ther.83 , 234 – 242 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Dunn OJ . Estimation of the means of dependent variables . Ann. Math. Stat.29 ( 4 ), 1095 – 1111 ( 1958 ).
   Google Scholar
• Weisstein EW . Noncentral F-Distribution ( 2002 ). http://mathworld.wolfram.com/NoncentralF-Distribution.html .
   Google Scholar
• Dodgen TM , LabuschagneCDJ , Van SchalkwykAet al. Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort . Pharmacogenomics J.16 , 566 – 572 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Gaedigk A , CoetseeC . The CYP2D6 gene locus in South African coloureds: unique allele distributions, novel alleles and gene arrangements . Eur. J. Clin. Pharmacol.64 ( 5 ), 465 – 475 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Wright GE , NiehausDJ , DrögemöllerBI , KoenL , GaedigkA , WarnichL . Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population . Ann. Hum. Genet.74 ( 4 ), 340 – 350 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Nakajima M , InoueT , ShimadaN , TokudomeS , YamamotoT , KuroiwaY . Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes . Drug Metab. Dispos.26 ( 3 ), 261 – 266 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Xie G , ZhouD , ChengK-W , WongCC , RigasB . Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans . Biochem. Pharmacol.85 ( 8 ), 1195 – 1202 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ziegler D , FonsecaV . From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy . J. Diabetes Complications29 ( 1 ), 146 – 156 ( 2015 ).
   PubMed Web of Science ®Google Scholar